Characteristics, treatment patterns, healthcare resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims data

Published: 6 June 2023| Version 1 | DOI: 10.17632/994227m9zy.1
Contributors:
Heide A. Stirnadel-Farrant, Xiao Xu, Justin Kwiatek, Priya Jain, Juliana Meyers, Sean Candrilli, Daniel Mines, Catherine J. Datto

Description

Supplementary material

Files

Categories

Autoimmunity, Steroid, Antibiotics, Opioid, Health Care Cost, Pemphigoid, Comorbidity, Disease Burden, Health Care Utilization, Skin Blistering, Bullous Disease

Funding

AstraZeneca (United Kingdom)

Licence